CHF Solutions Signs International Distribution and Services Agreement with Singapore-based TRANSMEDIC Pte Ltd.

EDEN PRAIRIE, Minn., Dec. 13, 2017 -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today that it has entered into an international distribution agreement with Singapore-based TRANSMEDIC Pte Ltd to market and support CHF Solutions’ Aquadex FlexFlow^® System in the region.

“We are very pleased to expand our market reach into Singapore with our new distributor partner, TRANSMEDIC Pte Ltd, a premier medical technology sales and distribution company serving hospitals, clinics and health-centers in Southeast Asia,” said John Erb, CEO of CHF Solutions. “TRANSMEDIC has the market reach and service breadth to meet our expansion goals as we continue to execute our US and international growth plans. We have been in contact with healthcare providers that already own Aquadex FlexFlow consoles, and we look forward to TRANSMEDIC being able to service those units, bring them back into use and expanding the usage in the area,” Mr. Erb concluded.

About TRANSMEDIC Pte Ltd.

Formed in 1980, TRANSMEDIC offers direct sales, education and training plus technical support and maintenance for numerous medical technology, supplying hospitals, clinics and health-centers with a range of high quality products from 40 different companies, incorporating the latest technological advances. From its head office in Singapore and 7 offices allover Southeast Asia, this organization of 400 people provide full coverage of the SouthEast region. TRANSMEDIC is committed to provide the medical profession with a range of quality products incorporating the latest technology and backed by the highest level of customer service and support.

About CHF Solutions

CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's  mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding meeting our international expansion goals and TRANSMEDIC being able to servicing existing Aquadex FlexFlow consoles,  bringing them back into use and expand the usage of Aquadex FlexFlow consoles.  Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Claudia Napal Drayton
Chief Financial Officer
CHF Solutions Inc.           
T: +1-952-345-4205

Investor Relations:
CHF Solutions, Inc.
[email protected]

-or-

Bret Shapiro
Managing Partner
CORE IR
516 222 2560
[email protected]
www.coreir.com